Impel NeuroPharma, Inc. (IMPL) financial statements (2022 and earlier)

Company profile

Business Address 201 ELLIOTT AVE. W
SEATTLE, WA 98119
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments88,212
Cash and cash equivalents88,212
Receivables1,374
Inventory, net of allowances, customer advances and progress billings2,824
Inventory2,824
Prepaid expense1,268
Other undisclosed current assets898
Total current assets:94,576
Noncurrent Assets
Property, plant and equipment3,149
Other noncurrent assets187
Total noncurrent assets:3,336
TOTAL ASSETS:97,912
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities15,317
Accounts payable6,367
Accrued liabilities8,950
Other undisclosed current liabilities637
Total current liabilities:15,954
Noncurrent Liabilities
Long-term debt and lease obligation29,450
Long-term debt, excluding current maturities29,450
Total noncurrent liabilities:29,450
Total liabilities:45,404
Stockholders' equity
Stockholders' equity attributable to parent52,508
Common stock23
Additional paid in capital267,283
Accumulated deficit(214,798)
Total stockholders' equity:52,508
TOTAL LIABILITIES AND EQUITY:97,912

Income statement (P&L) ($ in thousands)

12/31/2021
Revenues668
Cost of revenue(691)
Cost of goods and services sold(199)
Other undisclosed gross profit46
Gross profit:23
Operating expenses(71,463)
Other undisclosed operating loss(46)
Operating loss:(71,486)
Nonoperating expense
(Other Nonoperating expense)
(5,048)
Interest and debt expense(1,993)
Loss from continuing operations before equity method investments, income taxes:(78,527)
Other undisclosed income from continuing operations before income taxes1,993
Loss from continuing operations before income taxes:(76,534)
Income tax expense(2)
Net loss attributable to parent:(76,536)
Preferred stock dividends and other adjustments129
Other undisclosed net loss available to common stockholders, basic(258)
Net loss available to common stockholders, diluted:(76,665)

Comprehensive Income ($ in thousands)

12/31/2021
Net loss:(76,536)
Comprehensive loss, net of tax, attributable to parent:(76,536)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: